Basic Information
| LncRNA/CircRNA Name | NORAD |
| Synonyms | NA |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Luciferase reporter assay, RIP |
| Sample | lung adenocarcinoma tissues, cell line (H460 ,Hs578T, CL1-0, CL1-5, ZR75 and T47D) |
| Expression Pattern | down-regulated |
| Function Description | NORAD is downregulated in lung and breast cancers, and its low expression correlates with metastasis and adverse prognosis |
| Pubmed ID | 30967631 |
| Year | 2019 |
| Title | LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. |
External Links
| Links for NORAD | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |